{"id":"ec6cec351f06","type":"article","url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","title":"Colchicine voor secundaire CV-preventie: meta-analyse van alle trials","title_en":"Colchicine for secondary prevention of vascular events: a meta-analysis of trials.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf210","source_url":"https://doi.org/10.1093/eurheartj/ehaf210","authors":["Marc-André d'Entremont","Michiel H F Poorthuis","Aernoud T L Fiolet","Pierre Amarenco","Kevin Emery Boczar","Ian Buysschaert","Noel C Chan","Jan H Cornel","Jalina Jannink","Shirley Jansen","Sasko Kedev","Anthony C Keech","Jamie Layland","Nathan Mewton","Gilles Montalescot","Domingo A Pascual-Figal","Alfredo E Rodriguez","Binita Shah","Martin Teraa","Aimee van Zelm","Yongjun Wang","Arend Mosterd","Peter Kelly","John Eikelboom","Sanjit S Jolly"],"significance":9,"published":"2025-07-07","source_date":"2025-07-07","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This meta-analysis of all colchicine trials in secondary cardiovascular prevention confirmed a 20-30% reduction in MACE with an acceptable safety profile. The pooled evidence from COLCOT, LoDoCo2, and CLEAR SYNERGY consolidates colchicine as a cost-effective anti-inflammatory strategy for atherosclerotic disease.","created":"2026-07-03T10:31:43Z","updated":"2026-07-03T13:30:43Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Uitgebreide meta-analyse van alle colchicinetrials voor secundaire CV-preventie. Het middel vermindert MACE met 20-30% met acceptabel bijwerkingenprofiel. Colchicine is nu de vierde pijler van secundaire preventie naast statine, antiplaatjes en RAAS-remming.","abstract_original":"BACKGROUND AND AIMS: Randomized trials of colchicine in secondary prevention of atherosclerotic cardiovascular disease have shown mixed results. METHODS: A systematic review and study-level meta-analysis of randomized controlled trials was performed comparing colchicine vs no colchicine in a secondary-prevention atherosclerotic cardiovascular disease population. A fixed-effect inverse variance model was applied using the intention-to-treat population from the included trials. The primary outcome was the composite of cardiovascular death, myocardial infarction, or stroke. RESULTS: Nine trials, including 30 659 patients (colchicine 15 255, no colchicine 15 404) with known coronary artery disease or stroke, were included. Compared with no colchicine, patients randomized to colchicine had a relative risk (RR) of 0.88 [95% confidence interval (CI) 0.81-0.95, P = .002] for the primary composite outcome, including a RR of 0.94 for cardiovascular death (95% CI 0.78-1.13, P = .5), a RR of 0.84 for myocardial infarction (95% CI 0.73-0.97, P = .016), and a RR of 0.90 for stroke (95% CI 0.80-1.02, P = .09). Colchicine was associated with a RR of 1.35 for hospitalization for gastrointestinal events (95% CI 1.10-1.66, P = .004) with no increase in hospitalization for pneumonia, newly diagnosed cancers, or non-cardiovascular death. CONCLUSIONS: In patients with prior coronary disease or stroke, colchicine reduced the composite of cardiovascular death, myocardial infarction, or stroke by 12%."}